HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) AlzheimAlert™ test is literally years ahead of the competition, according to Brian Doyle, Nymox's Senior Manager for Worldwide Sales and Marketing. The urine-based test, which measures levels of a protein-based biomarker for Alzheimer’s disease, is currently available to physicians in major markets, including Europe and the United States. A recent article in The Wall Street Journal (“Detecting Alzheimer's Early,” December 12, 2006) described competing tests in this area that employ measuring multiple protein biomarkers and quoted a conservative estimate that these possible competitors were 3 to 5 years away from the clinic.
